ProShare Advisors LLC decreased its position in shares of AtriCure, Inc. (NASDAQ:ATRC – Get Rating) by 14.2% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 8,401 shares of the medical device company's stock after selling 1,385 shares during the quarter. ProShare Advisors LLC's holdings in AtriCure were worth $552,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also modified their holdings of ATRC. Pinebridge Investments L.P. purchased a new stake in AtriCure during the fourth quarter worth $56,000. First Horizon Advisors Inc. raised its stake in shares of AtriCure by 80.5% during the 4th quarter. First Horizon Advisors Inc. now owns 1,496 shares of the medical device company's stock worth $103,000 after buying an additional 667 shares during the last quarter. Islay Capital Management LLC purchased a new stake in shares of AtriCure in the 1st quarter worth about $117,000. Rockefeller Capital Management L.P. grew its stake in AtriCure by 10.1% in the 4th quarter. Rockefeller Capital Management L.P. now owns 2,341 shares of the medical device company's stock valued at $162,000 after acquiring an additional 215 shares during the last quarter. Finally, Ensign Peak Advisors Inc purchased a new position in AtriCure during the 4th quarter valued at about $203,000. Institutional investors and hedge funds own 95.21% of the company's stock.
Get
AtriCure alerts:
Analyst Ratings Changes
Several analysts have recently commented on the stock. Needham & Company LLC increased their price target on shares of AtriCure from $55.00 to $65.00 and gave the company a "buy" rating in a research report on Wednesday, August 3rd. StockNews.com downgraded AtriCure from a "hold" rating to a "sell" rating in a research report on Tuesday, August 23rd. BTIG Research reduced their price objective on AtriCure from $94.00 to $75.00 and set a "buy" rating on the stock in a research report on Friday, June 24th. Piper Sandler dropped their price objective on AtriCure from $90.00 to $55.00 and set an "overweight" rating for the company in a research report on Wednesday, August 3rd. Finally, Stifel Nicolaus reduced their target price on shares of AtriCure from $70.00 to $50.00 in a report on Monday, July 18th. One equities research analyst has rated the stock with a sell rating and five have given a buy rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $75.86.
AtriCure Trading Down 0.2 %
Shares of ATRC stock opened at $45.62 on Thursday. AtriCure, Inc. has a 1-year low of $32.83 and a 1-year high of $89.18. The firm's 50-day simple moving average is $46.19 and its 200-day simple moving average is $51.40. The firm has a market cap of $2.12 billion, a P/E ratio of 39.33 and a beta of 1.20. The company has a debt-to-equity ratio of 0.15, a current ratio of 3.66 and a quick ratio of 2.93.
AtriCure (NASDAQ:ATRC – Get Rating) last announced its quarterly earnings results on Tuesday, August 2nd. The medical device company reported ($0.32) earnings per share for the quarter, missing analysts' consensus estimates of ($0.30) by ($0.02). AtriCure had a net margin of 17.62% and a negative return on equity of 11.47%. During the same quarter last year, the business posted ($0.30) earnings per share. As a group, equities analysts forecast that AtriCure, Inc. will post -1.09 EPS for the current year.
AtriCure Profile
(Get Rating)
AtriCure, Inc develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems, and intercostal nerves to medical centers in the United States, Europe, Asia, and internationally. The company offers Isolator Synergy Clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and the Coolrail device, which enable users to make longer linear lines of ablation.
Read More
- Get a free copy of the StockNews.com research report on AtriCure (ATRC)
- Can Alibaba And Baidu Finally Rally With Delisting Fears Gone?
- 3 Materials Stocks That May Earn a Place on Your Watchlist
- Is World Wresting Entertainment Getting Ready to Be Sold?
- Crowdstrike Stock Retraces, As Earnings Sober Expectations
- Will The Institutions Buy The Dip In Ambarella Stock?
Receive News & Ratings for AtriCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure and related companies with MarketBeat.com's FREE daily email newsletter.
